Market Assessment
Strongbridge Biopharma (SBBP) is a small-cap ($161 million) commercial-stage biopharmaceutical company developing innovative therapies for rare diseases affecting the neuromuscular and endocrine systems (i.e., acromegaly and Cushing’s syndrome). Commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency.
Cushing’s syndrome is a metabolic disease triggered by excess secretion of cortisol. RECORLEV (levoketoconazole) is an investigational cortisol